Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.

Researchers at ETH Zurich have combined two gene editing methods. This enables them to quickly investigate the significance of many genetic mutations involved in the development and treatment of ...

The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease. However, researchers have now shown that there is a risk of inadvertently ...

The CRISPR molecular scissors have the potential to revolutionize the treatment of genetic diseases. This is because they can ...

The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease.

The research team has now succeeded in using the CRISPR system to insert the missing letters in the right place. They ...

The CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein) system is an adaptive immune system found in bacteria that provides defense against invading ...

Genomic DNA extraction was carried out by lysing cells using QuickExtract™ DNA Extraction Solution (Lucigen; Biozym QE09050). PCR primers were designed for each target to amplify the flanking region ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction in ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe ...